hsv529
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 23, 2013 (NCT01915212)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 1Immunity, active
Human herpesvirus 1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hsv529
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02571166 | Phase 1 | Nov 1, 2015 | Sanofi-Aventis, University of Washington |
| NCT01915212 | Phase 1 | Jul 23, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi-Aventis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi-Aventis | For profit | 2 | 0 | 1 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2013 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1